COLUMBIA — The University of Missouri System will see an increase in licensing revenues after a new agreement with GlaxoSmithKline.
Last week, pharmaceutical company Santarus granted exclusive rights to GlaxoSmithKline to commercialize prescription and over-the-counter drug Zegerid and to distribute and sell Zegerid in Puerto Rico and the U.S. Virgin Islands.
Zegerid, a drug used to prevent acid-reflux disease and ulcers, was developed at MU in the mid-1990s by Jeff Phillips of the MU School of Medicine and was patented in 2006. Santarus bought the rights for Zegerid in 2001.
“With more product in the marketplace, we would expect that sales, and therefore our royalty revenues, will increase,” said Scott Uhlmann, director of the Office of Intellectual Property Management for the UM System.
A 2007 UM Economic Development report noted that Zegerid has already brought over $10 million in revenues to UM, which has gone to university research programs.
The UM System had a considerable increase in licensing revenues between the 2006 and 2007 fiscal years. In fiscal 2007, UM licensing income doubled to more than $4.6 million from about $2.3 million in fiscal 2006.
Uhlmann attributes the revenue increase to an increase in the sale of licensed products as well as in revenues generated through multiple new agreements in the 2007 fiscal year.
Researchers at MU have also been filing more U.S. patent applications. The result was 15 U.S. patents issued and 16 new licenses and agreements signed in fiscal 2006; in fiscal 2007, 19 U.S. patents were issued and 17 licenses and agreements signed.
Agreements for fiscal 2007 include multiple technologies being licensed to United States Semiconductor Corporation, Mo-Sci Corporation and Alltech Associates Inc.
The UM System is attempting to double its licenses and agreements.
In fiscal 2007, there were 76 U.S. patent applications filed, 11 more than in 2006, and there have already been 34 U.S. patent applications filed since fiscal 2008 began.